News

Stock to BUY: Shares of SBI Life Insurance are back in focus after the insurer reported a solid set of numbers for the December quarter prompting several global brokerages to reiterate their bullish stance despite near term margin pressures from GST related changes. With robust growth in new business steady margins and improving product mix analysts believe the stock continues to justify a valuation premium over peers.

At the current market price of around Rs 2053 SBI Life remains one of the most widely tracked life insurers with brokerages highlighting its execution strength distribution reach and resilience in the face of regulatory headwinds.

The third quarter is seasonally important for life insurers and SBI Life delivered a healthy performance across key metrics. New business sales rose sharply aided by strong growth across channels and better traction in higher margin protection and participating savings products.

Value of New Business growth was strong year on year driven by a broad based rise in Annualised Premium Equivalent and an improving product mix. While margins moderated sequentially due to the full impact of GST input tax credit loss they remained well within the company guided range reassuring analysts on earnings visibility.

HSBC has maintained a Buy rating on SBI Life even as it trimmed its target price. The brokerage cited robust VNB growth in Q3 driven by strong APE momentum across key channels and a favourable mix of products.

HSBC believes SBI Life execution track record and an estimated eighteen percent compound annual growth rate in embedded value over the FY26 to FY28 period strengthen the case for a valuation premium over peers. It has also raised its VNB estimates for FY26 to FY28 reflecting confidence in the insurer medium term growth trajectory.

Bernstein Healthy growth in a seasonally critical quarter

Bernstein has reiterated its Outperform rating pointing out that SBI Life reported a healthy set of numbers in a crucial quarter. New sales growth stood out while margins held firm despite GST related headwinds.

The brokerage noted that management continues to guide for a gross GST impact in FY27 but expects the net impact on full year margins to be limited due to a better product mix. Bernstein also highlighted that growth trends remain ahead of FY26 guidance with margins tracking within the stated range.

Jefferies has maintained its Buy rating on SBI Life noting that Q3 VNB growth was in line with expectations. The brokerage attributed the performance to strong premium growth a richer mix and higher attachment of protection products and riders.

While the sharp acceleration in APE growth from the previous quarter is encouraging Jefferies pointed out that management has chosen to retain its FY26 growth guidance rather than upgrade it even as market expectations had turned more optimistic. Overall core operating trends were described as stable and predictable.

Goldman Sachs has raised its target price on SBI Life citing strong VNB growth driven by a more profitable product mix. The brokerage highlighted a sharp rise in participating savings products and steady momentum in retail protection helped by demand recovery following GST exemption.

ULIP sales also improved lifting their share in overall APE. While margins declined marginally year on year due to the full impact of input tax credit loss Goldman Sachs described the performance as commendable and said management guidance of a limited margin impact for the full year provides comfort.

Nomura has retained its Buy call on SBI Life noting that APE growth has been faster than management guidance and that the company is likely to deliver one of the strongest VNB growth profiles among listed life insurers in FY26.

The brokerage also flagged SBI Life relatively lower persistency challenges compared with peers and the successful scaling up of new participating products. While a high base may limit further margin expansion Nomura expects healthy growth momentum to continue into FY27.

Analysts broadly agree that SBI Life ability to balance growth and margins in a changing regulatory environment remains its key strength. Sustained traction in protection products stability in the banca channel and disciplined cost management will be critical over the next few quarters.

While near term margin volatility from GST related changes cannot be ruled out brokerages believe SBI Life is better placed than peers to absorb these pressures. For long term investors the consensus view suggests that the insurer scale execution and growth visibility continue to support a bullish outlook on the stock.